Hair loss is a well-known side effect of cancer treatment, and is listed among the most distressing aspects of chemotherapy treatment. However, hair loss from chemotherapy is usually a temporary condition, one that resolves once treatment has concluded. Persons around the United States who have been left with permanent hair loss from Taxotere are understandably outraged. Led to believe their hair would grow back, thousands of individuals have been left with patchy or clumpy hair, or with permanent baldness. Taxotere hair loss is a physical condition that results in negative body image, distress, and depression.
Sanofi, the company responsible for developing and marketing the chemotherapy drug, has known about the risk of Taxotere permanent hair loss for more than a decade, yet never warned American consumers. The company sponsored a study which was launched the year the drug was approved, 1996. In 2005, Sanofi obtained the study results and confirmed that permanent hair loss from Taxotere was a side effect among approximately 9% of patients. The company warned the medical community and the public of the risk for permanent hair loss from Taxotere in Canada and Europe, yet concealed the study results in the United States.
In addition to this widespread deception, Sanofi has attracted regulators' attention through its misrepresentation of Taxotere in advertising. In 2009, Sanofi received a FDA Taxotere warning letter for claiming the drug was more effective than comparable cancer treatments. In fact, there was no factual basis to this claim and Sanofi was warned to remove claims of "super efficacy" from its marketing materials.
A former Sanofi official has made further allegations against the company through a Taxotere lawsuit filed in Pennsylvania. The employee accused the company of fraudulent marketing, the payment of illegal kickbacks and unlawful incentives to physicians who used Taxotere for off-label uses. It is not illegal for doctors to use a drug for a use other than that which the FDA has approved, but drug companies are strictly forbidden from marketing or incentivizing off-label applications. Sanofi's efforts to promote Taxotere for a wide range of uses resulted in the drug becoming widely popular for use in cancer treatment; at its height, global Taxotere sales brought in $1.4 billion.
When a corporation deceives its consumers, when laws are broken or a executives engage in unethical business practices, and, above all, when innocent Americans are harmed by a dangerous drug, these Taxotere lawyers spring into action. It is our mission to pursue justice on behalf of individuals and families harmed by dangerous or defective products, no matter how complex the case. The attorneys handling Taxotere hair loss lawsuits believe that persons who have suffered permanent Taxotere hair loss may be entitled to significant compensation through filing a Taxotere lawsuit against Sanofi.
The Taxotere hair loss attorneys represent all persons involved in a Taxotere lawsuit on a contingency basis, meaning you will never pay legal fees unless we win for you. The Taxotere lawyers have a strong record of success in major pharmaceutical litigation -- for example, the firm won over $200 million in damages in three baby powder cancer lawsuits against Johnson & Johnson last year alone. Our expertise lies in the realm of product liability litigation, holding corporations accountable for the damage their products have caused among ordinary consumers.
For more information, visit our Taxotere Hair Loss website.